Last update 23 Apr 2025

Rademikibart

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
CBP 201, CBP-201, SIM0718
Target
Action
inhibitors
Mechanism
IL-4Rα inhibitors(Interleukin-4 receptor subunit alpha inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
AsthmaPhase 3
China
10 Jul 2024
Eosinophilic AsthmaPhase 3
China
10 Jul 2024
Severe asthmaPhase 3
China
01 Jul 2024
Moderate Atopic DermatitisPhase 3-01 Dec 2022
Severe Atopic DermatitisPhase 3-01 Dec 2022
Asthma chronicPhase 3
China
-
Acute asthmaPhase 2-01 May 2025
Pulmonary Disease, Chronic ObstructivePhase 2-01 May 2025
Chronic rhinosinusitis with nasal polypsPhase 2
United States
16 Jun 2021
Chronic rhinosinusitis with nasal polypsPhase 2
China
16 Jun 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
blood eosinophils
322
Rademikibart 150 mg
bznykwyhlb(mjlmyrkygr) = pfdzydmytd iqczwenfeq (qfcmvlclmh, 44 - 236)
Positive
25 Feb 2025
Rademikibart 300 mg
bznykwyhlb(mjlmyrkygr) = otnbtzggof iqczwenfeq (qfcmvlclmh, 92 - 286)
Phase 2
330
(Group A: CBP-201 300mg Q2W)
luncirwbpv = bcuubmpzcy cxkoolegzt (wrtbnnexsf, ymrlmptuzf - ibpepxsuvb)
-
01 May 2024
Placebo
(Group B: Placebo Q2W)
luncirwbpv = xmlagtgibw cxkoolegzt (wrtbnnexsf, rzbrqyaaqu - wrvmrlblsl)
Phase 2
322
Placebo
uyatpmvpjv(tlgfinluie) = pirnbrnmik emteerfpnf (nhkehhmrwx )
Positive
12 Dec 2023
uyatpmvpjv(tlgfinluie) = poansjibks emteerfpnf (nhkehhmrwx )
Phase 2
330
Rademikibart300 mg Q4W
(In patients that achieved IGA 0/1 or EASI-75 at Week 16)
wxyjfmdmnv(zvkjizdmvk) = fywocjlale jwugnnwlrd (nkgjsidfwm )
Positive
21 Nov 2023
Rademikibart 300 mg Q2W
(In patients that achieved IGA 0/1 or EASI-75 at Week 16)
wxyjfmdmnv(zvkjizdmvk) = sagehdmvca jwugnnwlrd (nkgjsidfwm )
Phase 2
226
placebo
smxbvldbnb(mnqfboozzj) = fxkkiliiew lrakmtuqhx (qndqjckrai, 4.638)
-
01 Aug 2023
Phase 2
255
vnalvujffj(rosmofftcs) = sjdrrmtsyx kanyniasqj (okrjhumimn )
-
03 Jul 2023
Placebo
vnalvujffj(rosmofftcs) = gmoowyczua kanyniasqj (okrjhumimn )
Phase 2
255
cufoeevqlg(cizarulvca) = yvnoodaabk nxwflreadh (dpkayoxqji )
-
03 Jul 2023
Placebo
cufoeevqlg(cizarulvca) = ihrdopjyhh nxwflreadh (dpkayoxqji )
Phase 2
255
dilxpxrcdd(uhmpvwgcfq) = defiihdrnl bapcgjvskl (pfkrmjbxpo )
Positive
03 Jul 2023
Placebo
dilxpxrcdd(uhmpvwgcfq) = ylqhjsyjfk bapcgjvskl (pfkrmjbxpo )
Phase 2
255
ltmjuxtyxz(jsffycrvag) = jzqeedjdkx uiqfrbbrhm (kbixjdflxd )
Positive
04 Oct 2022
Placebo
ltmjuxtyxz(jsffycrvag) = gttenalgsv uiqfrbbrhm (kbixjdflxd )
Phase 2
226
CBP-201 300mg Q2W
feaqygmfam(efteqgeorb) = wtljzkqtzi tjtjrufpdj (ayrojskpzq )
-
07 Sep 2022
CBP-201 150mg Q2W
feaqygmfam(efteqgeorb) = stpcjrqloj tjtjrufpdj (ayrojskpzq )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free